EQL Pharma AB (publ) (STO:EQL)

Market Cap	1.79B
Revenue (ttm)	397.94M
Net Income (ttm)	42.54M
Shares Out	29.53M
EPS (ttm)	1.41
PE Ratio	43.02
Forward PE	29.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,358
Average Volume	34,570
Open	59.00
Previous Close	59.10
Day's Range	58.30 - 60.70
52-Week Range	57.10 - 98.60
Beta	0.57
RSI	42.68
Earnings Date	Nov 5, 2025

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In 2024, EQL Pharma AB's revenue was 373.52 million, an increase of 41.39% compared to the previous year's 264.17 million. Earnings were 43.12 million, an increase of 89.93%.